中国医院用药评价与分析Issue(7)：913-914,2.DOI:10.14009/j.issn.1672-2124.2015.07.026
基础胰岛素与二肽基肽酶－4抑制剂联合治疗2型糖尿病的临床观察
Clinical Efficacy of Basic Insulin plus DPP-4 inhibitors for Type 2 Diabetes
范慧洁1
作者信息
- 1. 郑州人民医院内分泌科，河南郑州 450000
- 折叠
摘要
Abstract
OBJECTIVE:To study the clinical efficacy of basic insulin plus DPP 4 inhibitors for type 2 diabetes mellitus.METHODS:80 patients with type 2 diabetes whose fasting blood glucose level was >11.1 mmol/L were randomly divided into either treatment group or control group of 40 cases each.The treatment group was given insulin plus sitagliptin while the control was group given insulin plus repaglinide.The clinical efficacy of the two groups was recorded.RESULTS: As compared with before treatment, the fasting blood glucose, and the postprandial blood glucose(2 hours after meal), HBA1C, blood lipid profile and body mass index ( BMI) in the treatment group decreased significantly(P<0.05), showing better improvement in all the parameters than in the control group(P>0.05 );pancreatic beta cell function was significantly decreased in both groups after treatment as compared with before treatment, with the treatment group showing better improvement than in the control group( P<0.05) .There were few adverse drug reactions in the two groups and no statistically significant difference was noted between the two groups ( P>0.05 ) .No statistically significant differences were noted between the two groups regarding the blood glucose target-meeting rate and the median time to meet blood glucose target(P<0.05).CONCLUSIONS:Basic insulin plus DPP 4 inhibitors is safe and effective for type 2 diabetes, thus the use of which is worthy of clinical recommendation.关键词
2型糖尿病/二肽基肽酶-4抑制剂/胰岛素/疗效观察Key words
Type 2 diabetes/DPP-4 inhibitors/Insulin/Clinical observation分类
医药卫生引用本文复制引用
范慧洁..基础胰岛素与二肽基肽酶－4抑制剂联合治疗2型糖尿病的临床观察[J].中国医院用药评价与分析,2015,(7):913-914,2.
